CN113603802B - Preparation method and application of verbena polysaccharide - Google Patents
Preparation method and application of verbena polysaccharide Download PDFInfo
- Publication number
- CN113603802B CN113603802B CN202110974761.7A CN202110974761A CN113603802B CN 113603802 B CN113603802 B CN 113603802B CN 202110974761 A CN202110974761 A CN 202110974761A CN 113603802 B CN113603802 B CN 113603802B
- Authority
- CN
- China
- Prior art keywords
- verbena
- polysaccharide
- vop
- distilled water
- crude extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 title claims abstract description 84
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 title claims abstract description 84
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 title claims abstract description 84
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 title claims abstract description 84
- 150000004676 glycans Chemical class 0.000 title claims abstract description 71
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 71
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 240000001519 Verbena officinalis Species 0.000 title claims description 4
- 241001081203 Verbena Species 0.000 claims abstract description 83
- 239000000287 crude extract Substances 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 14
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 7
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 7
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 7
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 7
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 7
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 7
- 229930182830 galactose Natural products 0.000 claims abstract description 7
- 239000008103 glucose Substances 0.000 claims abstract description 7
- 108091005804 Peptidases Proteins 0.000 claims abstract description 6
- 239000004365 Protease Substances 0.000 claims abstract description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 6
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 6
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 238000000605 extraction Methods 0.000 claims description 40
- 235000000346 sugar Nutrition 0.000 claims description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000012153 distilled water Substances 0.000 claims description 16
- 238000009826 distribution Methods 0.000 claims description 16
- 238000010828 elution Methods 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 235000019419 proteases Nutrition 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 4
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 3
- 108010067770 Endopeptidase K Proteins 0.000 claims description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 235000018718 Verbena officinalis Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 239000011344 liquid material Substances 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 239000000413 hydrolysate Substances 0.000 claims 2
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 18
- 102000004169 proteins and genes Human genes 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 10
- 238000001556 precipitation Methods 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 238000004440 column chromatography Methods 0.000 abstract description 2
- 229920002521 macromolecule Polymers 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract 2
- 230000017854 proteolysis Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 14
- 230000003078 antioxidant effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 230000002000 scavenging effect Effects 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 5
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000007071 enzymatic hydrolysis Effects 0.000 description 5
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- -1 IL-1β Proteins 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 101150109636 Inos gene Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 231100001083 no cytotoxicity Toxicity 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940107117 verbena extract Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241001073567 Verbenaceae Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Sustainable Development (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域technical field
本发明属于医药技术领域,具体涉及一种马鞭草多糖的制备方法与应用。The invention belongs to the technical field of medicine, and in particular relates to a preparation method and application of verbena polysaccharide.
背景技术Background technique
马鞭草(Verbena Officinalis)为马鞭草科、马鞭草属植物的全草,在我国分布范围较广,资源丰富。中药马鞭草性味苦,具有活血散瘀、解毒和利水消肿等功效,主要用于治疗经闭痛经、痈肿、疟疾、水肿、热淋等疾病。Verbena Officinalis is the whole plant of the Verbena family and the genus Verbena. It has a wide distribution range in my country and is rich in resources. Verbena, a traditional Chinese medicine, is bitter in taste and has the functions of promoting blood circulation and removing blood stasis, detoxification, diuresis and swelling.
国内外对马鞭草的研究主要侧重于其醇溶性及水煎粗提物的化学成分上,对水溶性马鞭草多糖的研究也仅限于粗多糖水平。Chao-Chao Jin等(Optimization ofpolysaccharides extracted from Verbena officinalis L and their inhibitoryeffects on invasion and metastasis of colorectal cancer cells[J].TropicalJournal of Pharmaceutical Research,2017,16(10):2387- 2394)优化了马鞭草粗多糖的提取工艺,得到最佳提取条件是液料比27.5:1(mL/g),提取时间92min,回流提取2次,在此条件下多糖实际提取率为1.48±0.06%,同时所得粗多糖具有抑制结肠癌细胞转移的作用。The research on Verbena at home and abroad mainly focuses on its alcohol solubility and the chemical composition of the crude extract of decoction. Chao-Chao Jin et al. (Optimization of polysaccharides extracted from Verbena officinalis L and their inhibitory effects on invasion and metastasis of colorectal cancer cells[J].TropicalJournal of Pharmaceutical Research,2017,16(10):2387- 2394) optimized the crude polysaccharide of Verbena The optimal extraction conditions are: liquid-solid ratio of 27.5:1 (mL/g), extraction time of 92 min, and reflux extraction twice. Under these conditions, the actual extraction rate of polysaccharides is 1.48±0.06%. At the same time, the obtained crude polysaccharides have Inhibition of colon cancer cell metastasis.
上述现有技术对马鞭草多糖的研究仅限于粗多糖水平,且所得粗多糖成分不明确,因此对于马鞭草多糖的制备方法及其主要特征有必要进行深入研究,以期为化妆品所添加的天然生物活性物质的研发,以及药物成分的替代产品开发提供新的对象。The research of the above-mentioned prior art to the verbena polysaccharide is limited to the crude polysaccharide level, and the obtained crude polysaccharide composition is not clear, so it is necessary to carry out in-depth research on the preparation method of the verbena polysaccharide and its main characteristics, with a view to the natural organisms added to cosmetics. The development of active substances, as well as the development of alternative products for pharmaceutical ingredients provides new targets.
发明内容SUMMARY OF THE INVENTION
本发明的目的之一,在于提供一种提高马鞭草多糖提取率的马鞭草多糖的制备方法,包括如下步骤:One of the objects of the present invention is to provide a kind of preparation method of verbena polysaccharide improving the extraction rate of verbena polysaccharide, comprising the steps:
(1)取干燥的马鞭草粉末,按照液料比20:1~100:1加入蒸馏水,恒温水浴锅65~95℃水浴提取120~240min,离心去除沉淀,得到粗提液;(1) take the dried verbena powder, add distilled water according to the liquid-material ratio of 20:1~100:1, extract in a constant temperature water bath at 65~95 ℃ for 120~240min, and centrifuge to remove the precipitation to obtain a crude extract;
(2)将步骤(1)所得的粗提液浓缩,加入浓缩液体积2~3倍的无水乙醇,4℃放置一定时间,5000r/min离心5min,取沉淀干燥后得马鞭草粗提物;(2) Concentrating the crude extract obtained in step (1), adding absolute ethanol with 2 to 3 times the volume of the concentrated solution, placing at 4°C for a certain period of time, centrifuging at 5000 r/min for 5 min, taking the precipitate and drying to obtain the crude extract of Verbena ;
(3)将步骤(2)所得马鞭草粗提物500mg溶解于20mL蒸馏水,加入蛋白酶,37℃水浴保温48h,5000r/min离心5min,去除沉淀,得到酶解液;(3) Dissolving 500 mg of the crude verbena extract obtained in step (2) in 20 mL of distilled water, adding protease, keeping at 37° C. water bath for 48 h, centrifuging at 5000 r/min for 5 min, removing the precipitation, and obtaining an enzymatic hydrolysis solution;
(4)取步骤(3)所得酶解液上DEAE-Sepharose CL-6B层析柱,调节流速1mL/min,用蒸馏水洗脱16~20h,然后使用0.2~0.4mol/L NaCl溶液进行梯度洗脱,自动部分收集器设定每管收集12mL洗脱液,根据糖及蛋白质含量分布情况,合并第20~40管洗脱液,用截留分子量3500~5000的透析袋对收集液进行透析,流水和蒸馏水各透析24h,透析液浓缩后冷冻干燥,得到马鞭草多糖VOP,马鞭草多糖VOP的平均提取率为8.3%以上。(4) Take the enzymatic hydrolysis solution obtained in step (3) and place it on a DEAE-Sepharose CL-6B chromatography column, adjust the flow rate to 1 mL/min, elute with distilled water for 16-20 h, and then use 0.2-0.4 mol/L NaCl solution for gradient washing The automatic partial collector is set to collect 12 mL of eluate in each tube. According to the distribution of sugar and protein content, the 20th to 40th tubes are combined, and the collected solution is dialyzed with a dialysis bag with a molecular weight cut-off of 3500 to 5000. Dialyzed with distilled water for 24 hours, the dialysate was concentrated and then freeze-dried to obtain verbena polysaccharide VOP. The average extraction rate of verbena polysaccharide VOP was over 8.3%.
优选方式下,步骤(1)中取干燥的马鞭草粉末,按照液料比20:1加入蒸馏水,恒温水浴锅83℃水浴提取210min,5000r/min离心10min去除沉淀,得到粗提液。In a preferred manner, in step (1), take the dried verbena powder, add distilled water according to the liquid-material ratio of 20:1, extract in a constant temperature water bath at 83° C. for 210 min, and centrifuge at 5000 r/min for 10 min to remove the precipitation to obtain a crude extract.
优选方式下,所述步骤(2)中将步骤(1)所得的粗提液浓缩40倍,加入浓缩液体积2倍的无水乙醇。In a preferred manner, in the step (2), the crude extract obtained in the step (1) is concentrated by 40 times, and anhydrous ethanol with 2 times the volume of the concentrated solution is added.
优选方式下,所述步骤(3)中蛋白酶包括4mg胰蛋白酶和4mg蛋白酶K。In a preferred manner, the protease in the step (3) includes 4 mg of trypsin and 4 mg of proteinase K.
优选方式下,所述步骤(4)中用蒸馏水洗脱16h,透析袋截留分子量3500。In a preferred manner, in the step (4), distilled water is used for elution for 16 hours, and the molecular weight cut-off of the dialysis bag is 3500.
优选方式下,所述步骤(4)所得的马鞭草多糖是均一杂多糖,重均分子量是290KDa,单糖组成是半乳糖,葡萄糖,甘露糖,鼠李糖和阿拉伯糖,各单糖摩尔比为2.8:1.5:1:1:1.4。In a preferred manner, the verbena polysaccharide obtained in the step (4) is a homogeneous heteropolysaccharide, the weight average molecular weight is 290KDa, the monosaccharide composition is galactose, glucose, mannose, rhamnose and arabinose, and the molar ratio of each monosaccharide is galactose, glucose, mannose, rhamnose and arabinose. is 2.8:1.5:1:1:1.4.
采用上述技术方案,本发明的有益效果是:Adopting the above-mentioned technical scheme, the beneficial effects of the present invention are:
(1)本发明所使用响应曲面法优化了马鞭草总糖提取工艺,特别是水溶性马鞭草多糖,相较于已报道的马鞭草总糖提取方法,提取率提高近5倍。(1) The response surface method used in the present invention optimizes the extraction process of verbena total sugar, especially the water-soluble verbena polysaccharide. Compared with the reported extraction method of verbena total sugar, the extraction rate is increased by nearly 5 times.
(2)本发明首先使用2~3倍体积无水乙醇对马鞭草多糖进行初步分离,其次将粗多糖进行酶解,蛋白酶可以水解大分子蛋白,可以释放原本与蛋白质缠绕在一起的多糖,酶解产物再经特定的柱层析纯化即可获得所述马鞭草多糖。该方法步骤简单,效果显著,只需准确掌握各步骤实验参数,即可获得成分均一的马鞭草多糖。(2) The present invention firstly uses 2 to 3 times the volume of absolute ethanol to preliminarily separate the verbena polysaccharide, and secondly, the crude polysaccharide is enzymatically hydrolyzed. The protease can hydrolyze the macromolecular protein and can release the polysaccharide originally entangled with the protein. The hydrolyzed product can be purified by specific column chromatography to obtain the verbena polysaccharide. The method has simple steps and remarkable effect, and only needs to accurately grasp the experimental parameters of each step, and then the verbena polysaccharide with uniform composition can be obtained.
(3)采用本发明制备得到的马鞭草多糖VOP成分明确,由均一杂多糖构成,重均分子量为290KDa,单糖组成是半乳糖,葡萄糖,甘露糖,鼠李糖和阿拉伯糖组成,其摩尔比为2.8:1.5:1:1:1.4。(3) The Verbena polysaccharide VOP prepared by the present invention has clear components, is composed of homogeneous heteropolysaccharides, has a weight-average molecular weight of 290KDa, and is composed of galactose, glucose, mannose, rhamnose and arabinose, and its molar composition is 290KDa. The ratio is 2.8:1.5:1:1:1.4.
(4)本发明制备得到的马鞭草多糖VOP在75μg/mL质量浓度下能够显著降低脂多糖诱导的RAW264.7细胞中炎症相关因子TNF-α、IL-1β、IL-6、COX-2和iNOS的mRNA相对表达量(P<0.05),具有显著的抗炎作用,无细胞毒。同时该多糖对超氧自由基和ABTS 自由基具有显著的清除作用,清除效果相当于维生素C,抗氧化作用显著。(4) The verbena polysaccharide VOP prepared by the present invention can significantly reduce the inflammation-related factors TNF-α, IL-1β, IL-6, COX-2 and lipopolysaccharide-induced RAW264.7 cells at a mass concentration of 75 μg/mL. The relative mRNA expression of iNOS (P<0.05) showed significant anti-inflammatory effect and no cytotoxicity. At the same time, the polysaccharide has a significant scavenging effect on superoxide free radicals and ABTS free radicals, the scavenging effect is equivalent to vitamin C, and the antioxidant effect is remarkable.
本发明的另一目的,在于提供一种所述马鞭草多糖的应用,所述马鞭草多糖应用于化妆品,以及医药用抗炎制剂的制备。Another object of the present invention is to provide an application of the verbena polysaccharide, the verbena polysaccharide being applied to cosmetics, and the preparation of medicinal anti-inflammatory preparations.
附图说明Description of drawings
图1为本发明实施例1马鞭草总糖提取率与液料比关系曲线Fig. 1 is the relationship curve of the total sugar extraction rate of Verbena and the ratio of liquid to material in Example 1 of the present invention
图2为本发明实施例1马鞭草总糖提取率与提取时间关系曲线Fig. 2 is the relation curve of extraction rate and extraction time of total sugar of Verbena in Example 1 of the present invention
图3为本发明实施例1马鞭草总糖提取率与提取温度关系曲线Fig. 3 is the relation curve of extraction rate and extraction temperature of total sugar of Verbena in Example 1 of the present invention
图4为本发明实施例1残差正态概率分布图Fig. 4 is a residual normal probability distribution diagram of
图5为本发明实施例1模型诊断图.(a):残差图;(b):预测值与实际值散点图Fig. 5 is a model diagnosis diagram of the embodiment of the
图6为本发明实施例2酶解后的VO1经0.2-0.4M NaCl梯度洗脱后糖(a)和蛋白质(b)分布曲线Figure 6 is the distribution curve of sugar (a) and protein (b) after VO1 after enzymatic hydrolysis in Example 2 of the present invention is eluted with a gradient of 0.2-0.4M NaCl
图7为本发明实施例2VOP的高效液相色谱图Fig. 7 is the high performance liquid chromatogram of the embodiment of the present invention 2VOP
图8为本发明实施例2VOP的全波长扫描图FIG. 8 is a full-wavelength scanning diagram of VOP in
图9为本发明实施例2VO2-P的高效液相色谱图Fig. 9 is the high performance liquid chromatogram of the embodiment of the present invention 2VO2-P
图10为本发明实施例2未酶解VO1经0.2-0.4M NaCl梯度洗脱后糖(a)和蛋白质(b)分布曲线Figure 10 shows the distribution curves of sugar (a) and protein (b) after the unenzymatic hydrolyzed VO1 in Example 2 of the present invention was eluted with a gradient of 0.2-0.4M NaCl
图11为本发明实施例2经0-1M NaCl梯度洗脱后糖(a)和蛋白质(b)分布曲线Figure 11 is the distribution curve of sugar (a) and protein (b) after 0-1M NaCl gradient elution in Example 2 of the present invention
图12为本发明实施例2经0-1M NaCl梯度洗脱糖的全波长扫描图Figure 12 is a full-wavelength scanning diagram of the 0-1M NaCl gradient elution of sugar in Example 2 of the present invention
图13为本发明实施例3马鞭草多糖VOP的气相色谱图.(图中1-5分别代表葡萄糖,半乳糖,甘露糖,鼠李糖和阿拉伯糖)Fig. 13 is the gas chromatogram of Verbena polysaccharide VOP in Example 3 of the present invention. (1-5 in the figure represent glucose, galactose, mannose, rhamnose and arabinose respectively)
图14为本发明实施例4VOP对RAW264.7小鼠巨噬细胞生长的抑制作用Figure 14 shows the inhibitory effect of VOP on the growth of RAW264.7 mouse macrophages in Example 4 of the present invention
图15为本发明实施例4VOP对LPS刺激RAW264.7小鼠巨噬细胞炎症因子mRNA表达的影响.(a):TNF-α;(b):IL-1β;(c):IL-6;(d):COX-2(图中不同字母代表差异显著,P<0.05)Figure 15 shows the effect of VOP in Example 4 of the present invention on the mRNA expression of inflammatory factors in RAW264.7 mouse macrophages stimulated by LPS. (a): TNF-α; (b): IL-1β; (c): IL-6; (d): COX-2 (different letters in the figure represent significant differences, P<0.05)
图16为本发明实施例4VOP对LPS刺激RAW264.7小鼠巨噬细胞iNOS基因表达的影响. (图中不同字母代表差异显著,P<0.05)Figure 16 shows the effect of VOP in Example 4 of the present invention on LPS-stimulated iNOS gene expression in RAW264.7 mouse macrophages. (Different letters in the figure represent significant differences, P<0.05)
图17为本发明实施例5VOP的抗氧化活性.(a):超氧自由基;(b):羟自由基;(c):ABTSFig. 17 is the antioxidant activity of the embodiment of the present invention 5VOP. (a): superoxide radical; (b): hydroxyl radical; (c): ABTS
具体实施方式Detailed ways
以下通过具体实施方式对本发明的技术方案进行进一步的说明和描述。The technical solutions of the present invention will be further illustrated and described below through specific embodiments.
实施例1马鞭草总糖的提取工艺优化
实验方法:采用单因素法和响应曲面实验法优化马鞭草总糖提取工艺,通过研究液料比,提取时间和提取温度几个因素,优化马鞭草总糖提取率。单因素实验是在固定两个实验因素条件下,只考察第3个实验因素,从而可以得到该因素的最适实验水平。Experimental method: The single factor method and response surface experiment method were used to optimize the extraction process of total sugar in Verbena, and the extraction rate of total sugar in Verbena was optimized by studying several factors such as the ratio of liquid to material, extraction time and extraction temperature. The single factor experiment is to examine only the third experimental factor under the condition of fixing two experimental factors, so that the optimal experimental level of this factor can be obtained.
为了优化马鞭草总糖的提取工艺,采用响应曲面实验和Box-Behnken设计方案,以液料比、提取时间和提取温度为实验因素,称取1g马鞭草粉末加入适量蒸馏水,进行每个实验,采用苯酚-硫酸法检测粗提液的马鞭草总糖提取率。In order to optimize the extraction process of total sugar of verbena, response surface experiment and Box-Behnken design scheme were used, taking the ratio of liquid to material, extraction time and extraction temperature as experimental factors, weighing 1 g of verbena powder and adding an appropriate amount of distilled water to carry out each experiment, The phenol-sulfuric acid method was used to detect the extraction rate of total sugar of Verbena in the crude extract.
实验结果:Experimental results:
研究料液比、提取时间和提取温度对马鞭草总糖提取率的影响,单因素实验结果如图 1、图2和图3所示。根据单因素实验结果,选取每个因素的3个实验水平,以便进行后续响应曲面实验。The effects of solid-liquid ratio, extraction time and extraction temperature on the extraction rate of total sugar in Verbena were studied. The results of single factor experiment are shown in Figure 1, Figure 2 and Figure 3. According to the results of the single factor experiment, 3 experimental levels of each factor were selected for subsequent response surface experiments.
根据单因素实验结果,料液比的三个水平确定为20:1、60:1、100:1,以65℃、80℃、95℃作为提取温度的三个水平,提取时间的三个水平为30min、120min、210min,马鞭草总糖提取率代码定为Y。响应面试验设计因素与水平见表1,试验设计方案及试验结果如表2所示。According to the results of the single factor experiment, the three levels of the solid-liquid ratio are determined as 20:1, 60:1, and 100:1, with 65°C, 80°C, and 95°C as the three levels of extraction temperature and the three levels of extraction time. For 30min, 120min, 210min, the code of total sugar extraction rate of verbena is set as Y. The factors and levels of the response surface test design are shown in Table 1, and the experimental design scheme and test results are shown in Table 2.
表1 响应面试验设计因素水平及编码Table 1 Response surface test design factor levels and codes
表2 马鞭草总糖提取率的Box-Behnken试验设计与结果Table 2 Box-Behnken experimental design and results of total sugar extraction rate of verbena
采用Design-Expert.V11.1.0软件对试验结果进行统计处理,利用数据拟合计算出回归方程模型为The Design-Expert.V11.1.0 software was used to statistically process the test results, and the regression equation model was calculated by data fitting as
Y=7.45-0.4662A+1.68B+0.6100C+0.0125AB-0.4450AC-0.7700BC-2.21 53A2-0.6702B2-0.7178C2。为验证该模型对提取方案进行预测的效果,进一步确定各因素对马鞭草多糖提取率的影响程度,对回归方程进行方差分析,结果见表3。Y=7.45-0.4662A+1.68B+0.6100C+0.0125AB-0.4450AC - 0.7700BC - 2.2153A2-0.6702B2-0.7178C2 . In order to verify the effect of the model on the prediction of the extraction scheme, and to further determine the degree of influence of various factors on the extraction rate of verbena polysaccharide, the regression equation was analyzed by variance, and the results are shown in Table 3.
表3 回归方程方差分析和显著性结果Table 3 Regression equation analysis of variance and significant results
根据数据结果得出的建议模型为Quadratic模型,此模型的p值为0.0224(<0.05),回归模型显著,失拟项p为0.2381(>0.05),失拟项不显著,说明模型对试验结果拟合性较好。方程的R2为0.8660,方程拟合程度较好,可利用此模型来分析和预测马鞭草多糖的提取率。从回归方程中各参数对马鞭草总糖的提取率的影响程度来看,B对响应值(提取率)的影响极显著(p<0.01)。According to the data results, the proposed model is Quadratic model, the p value of this model is 0.0224 (<0.05), the regression model is significant, the lack of fit item p is 0.2381 (>0.05), and the lack of fit item is not significant, indicating that the model has no effect on the test results. Good fit. The R 2 of the equation was 0.8660, and the fitting degree of the equation was good. This model could be used to analyze and predict the extraction rate of verbena polysaccharides. Judging from the influence degree of each parameter in the regression equation on the extraction rate of total sugar of Verbena, the influence of B on the response value (extraction rate) was extremely significant (p<0.01).
不仅方差分析结果可以分析模型是否可用,诊断图也可以诊断预测模型是否具有充分性。残差的正态图如图4所示,残差分布在对角线上表明残差服从正态分布,模型可靠。诊断图如图5所示,所有数据点在可接受范围内(±4.82),线性拟合图表明实际收益率和预测收益率之间存在良好的相关性。Not only can the ANOVA results analyze whether the model is available, but the diagnostic plot can also diagnose the adequacy of the predictive model. The normal map of the residuals is shown in Figure 4. The residuals are distributed on the diagonal line, indicating that the residuals obey the normal distribution and the model is reliable. The diagnostic plot is shown in Figure 5, all data points are within the acceptable range (±4.82), and the linear fit plot shows a good correlation between actual and predicted returns.
通过响应面法优化,软件分析给出提取马鞭草总糖的最优条件为A(液料比)=20:1,B(时间)=210min,C(温度)=83℃,此时预测的Y值=8.72829。按此方案进行3 次平行试验,实际测得马鞭草总糖的平均提取率为8.37±0.04%。通过响应曲面法优化马鞭草总糖提取工艺,建立了提取率预测模型,得到了最佳提取条件。Through the optimization of the response surface method, the software analysis gives the optimal conditions for extracting the total sugar of Verbena: A (liquid to material ratio) = 20:1, B (time) = 210min, C (temperature) = 83 °C, and the predicted Y value = 8.72829. Three parallel experiments were carried out according to this scheme, and the actual average extraction rate of total sugar of verbena was 8.37±0.04%. The extraction process of verbena total sugar was optimized by response surface method, the extraction rate prediction model was established, and the optimal extraction conditions were obtained.
实施例2马鞭草多糖的分离纯化,包括如下步骤:The separation and purification of
(1)马鞭草晒干,取干燥的马鞭草粉末200g,加入4000mL蒸馏水,恒温水浴锅 83℃水浴提取210min,5000r/min离心10min,去除沉淀,得到粗提液;(1) Sun-drying Verbena, taking 200g of dried Verbena powder, adding 4000mL of distilled water, extracting in a constant temperature water bath at 83°C for 210min, centrifuging at 5000r/min for 10min, removing the precipitation, and obtaining a crude extract;
(2)将步骤(1)所得的粗提取液利用旋转蒸发仪浓缩至100mL,加入200mL无水乙醇,4℃冰箱放置过夜,5000r/min离心5min,取沉淀干燥后得马鞭草粗提物(命名为VO1);(2) the crude extract obtained in step (1) was concentrated to 100 mL using a rotary evaporator, 200 mL of absolute ethanol was added, placed in a refrigerator at 4 °C overnight, centrifuged at 5000 r/min for 5 min, and the crude extract of Verbena was obtained after the precipitate was dried ( named VO1);
(3)将步骤(2)所得马鞭草粗提物500mg溶解于20mL蒸馏水,加入4mg胰蛋白酶和4mg蛋白酶K,37℃水浴保温48h,5000r/min离心5min,去除沉淀,得到酶解液;(3) 500 mg of the crude verbena extract obtained in step (2) was dissolved in 20 mL of distilled water, 4 mg of trypsin and 4 mg of proteinase K were added, the temperature was kept in a water bath at 37° C. for 48 h, and centrifuged at 5000 r/min for 5 min to remove the precipitate to obtain an enzymatic hydrolyzate;
(4)取步骤(3)所得酶解液上DEAE-Sepharose CL-6B层析柱(直径4.6cm,高35cm),调节流速1mL/min,用蒸馏水洗脱16h,不收集洗脱液,然后使用0.2-0.4mol/L NaCl溶液进行梯度洗脱,自动部分收集器设定每管收集12mL洗脱液,根据糖及蛋白质含量分布情况,合并第20~40管洗脱液,用截留分子量3500的透析袋对收集液进行透析,流水和蒸馏水各透析24h,透析液浓缩后冷冻干燥,得到马鞭草多糖VOP。(4) Take the enzymolysis solution obtained in step (3) and place it on a DEAE-Sepharose CL-6B chromatographic column (4.6 cm in diameter, 35 cm in height), adjust the flow rate to 1 mL/min, elute with distilled water for 16 h, and do not collect the eluent, then Use 0.2-0.4mol/L NaCl solution for gradient elution, set the automatic partial collector to collect 12 mL of eluate in each tube, and combine the 20-40 tubes according to the distribution of sugar and protein content, and use a molecular weight cut-off of 3500. The collected liquid was dialyzed with a dialysis bag, and dialyzed with running water and distilled water for 24 hours each. The dialysate was concentrated and then freeze-dried to obtain the verbena polysaccharide VOP.
结果:步骤(4)中使用0.2-0.4mol/L NaCl溶液进行梯度洗脱,洗脱曲线如图6所示,根据图6可以看出20~40管洗脱液检测出一个糖峰,同时280nm也检测出蛋白质峰,其中20~40管蛋白质分布情况与糖分布曲线峰型和管数吻合,说明是结合蛋白,收集20~40 管洗脱液得到本发明所述马鞭草多糖VOP。图7是VOP的高效液相色谱图,可以看出,峰型单一对称,说明VOP均一性好。图8是VOP的紫外吸收光谱图,可以看出,280nm 有吸收峰,是VOP的结合蛋白,除此之外无其它杂质。Results: In step (4), 0.2-0.4mol/L NaCl solution was used for gradient elution, and the elution curve was shown in Figure 6. According to Figure 6, it can be seen that 20-40 tubes of eluent detected a sugar peak, and at the same time Protein peaks were also detected at 280 nm, among which 20-40 tubes of protein distribution were consistent with the peak shape of the sugar distribution curve and the number of tubes, indicating that it was bound protein, and 20-40 tubes of eluate were collected to obtain the verbena polysaccharide VOP of the present invention. Figure 7 is the high performance liquid chromatogram of VOP, it can be seen that the peak shape is single and symmetrical, indicating that the uniformity of VOP is good. Figure 8 is the UV absorption spectrum of VOP, it can be seen that there is an absorption peak at 280 nm, which is the binding protein of VOP, and there are no other impurities.
步骤(2)使用2倍体积无水乙醇进行初步分离,得到马鞭草粗提物,其中乙醇的使用倍数比较重要。为了对比,实验还使用了4倍体积无水乙醇进行分离,得到的粗多糖命名为VO2。将粗提物VO2经同样方法进行层析,按照糖分布曲线将洗脱的主要糖进行收集,透析、浓缩后干燥,得到多糖命名为VO2-P。VO2-P高效液相色谱分析结果如图9 所示,可以看出VO2-P在5min后出现2个峰,说明可能含有其它成分或杂质,VO2-P 与VOP的高效液相色谱分析结果不同,说明二者所含成分不同。进一步说明,使用4倍体积乙醇分离得到的粗提物经后续同样方法纯化后,得到的多糖含有其它成分。Step (2) uses 2 times the volume of anhydrous ethanol for preliminary separation to obtain the crude extract of Verbena, wherein the use multiple of ethanol is more important. For comparison, the experiment also used 4 times the volume of absolute ethanol for separation, and the obtained crude polysaccharide was named VO2. The crude extract VO2 was chromatographed by the same method, and the eluted main sugars were collected according to the sugar distribution curve, dialyzed, concentrated and dried to obtain a polysaccharide named VO2-P. The results of VO2-P HPLC analysis are shown in Figure 9. It can be seen that VO2-P has two peaks after 5 minutes, indicating that it may contain other components or impurities. The HPLC analysis results of VO2-P and VOP are different , indicating that the two components contain different components. It is further explained that the obtained polysaccharide contains other components after the crude extract separated by 4 times the volume of ethanol is purified by the same method.
步骤(3)使用酶解后的糖样进行步骤(4)层析,效果显著。为了对比,不使用酶解液进行后续层析结果如图10,与酶解后洗脱图6对比,可以看出二者糖含量分布曲线没有变化,只有1个糖峰。但是图10蛋白质分布杂乱,峰型宽,说明蛋白质多,而图6的蛋白质分布明显区分出2个以上峰。蛋白质与糖都属于大分子,难以分离,经常聚合缠绕在一起,将糖样进行酶解,蛋白质被降解,释放出原本缠绕在一起的多糖,再上层析柱后,层析柱的离子交换功能可以轻易的将电荷含量通常较多的蛋白质留在后面洗脱出来,从而简单的达到了去除蛋白质杂质的目的。In step (3), the enzymatically hydrolyzed sugar sample is used to perform the chromatography in step (4), and the effect is remarkable. For comparison, the results of subsequent chromatography without using the enzymatic hydrolysis solution are shown in Figure 10. Compared with Figure 6 of the elution after enzymatic hydrolysis, it can be seen that the sugar content distribution curve of the two has not changed, and there is only one sugar peak. However, the protein distribution in Figure 10 is chaotic and the peak shape is broad, indicating that there are many proteins, while the protein distribution in Figure 6 clearly distinguishes more than two peaks. Proteins and sugars are macromolecules and are difficult to separate. They are often polymerized and entangled together. The sugar samples are enzymatically hydrolyzed, the protein is degraded, and the originally entangled polysaccharides are released. After being applied to the chromatography column, the ion exchange of the chromatography column The function can easily leave the protein with more charge content behind to elute out, so as to simply achieve the purpose of removing protein impurities.
步骤(4)中使用的0.2-0.4mol/L NaCl溶液进行梯度洗脱,使用浓度非常重要。浓度过大则离子强度大,随着马鞭草多糖的洗脱会随之洗脱出其它杂质,浓度太小则洗脱不出目标多糖,经试验摸索NaCl浓度为0.2-0.4mol/L为宜。图11是使用更大范围0-1mol/LNaCl溶液进行洗脱后结果,对比图6可以看出,蛋白质分布杂乱,没有进行有效的分离。进一步的收集洗脱液,浓缩后冻干得到多糖,将所得多糖进行紫外光谱扫描,结果图12,在280nm和350nm检测到两个吸收峰,说明含有蛋白质和羰基类化合物。对比使用0.2-0.4 mol/LNaCl洗脱所得VOP的紫外吸收光谱图(图8),使用0-1mol/L NaCl溶液洗脱所得多糖含有杂质,主要是350nm所示物质,如羰基类化合物。The 0.2-0.4 mol/L NaCl solution used in step (4) is subjected to gradient elution, and the concentration used is very important. If the concentration is too large, the ionic strength will be high. With the elution of verbena polysaccharide, other impurities will be eluted. If the concentration is too small, the target polysaccharide will not be eluted. After experiments, it is found that the NaCl concentration is 0.2-0.4mol/L. . Figure 11 shows the results after elution with a wider range of 0-1 mol/L NaCl solution. Compared with Figure 6, it can be seen that the protein distribution is chaotic and effective separation is not carried out. The eluate was further collected, concentrated and lyophilized to obtain polysaccharide, and the obtained polysaccharide was subjected to ultraviolet spectrum scanning. The results are shown in Figure 12. Two absorption peaks were detected at 280 nm and 350 nm, indicating that it contained proteins and carbonyl compounds. Compared with the UV absorption spectrum of VOP obtained by elution with 0.2-0.4 mol/L NaCl (Fig. 8), the polysaccharide obtained by elution with 0-1 mol/L NaCl solution contains impurities, mainly substances at 350 nm, such as carbonyl compounds.
实施例3马鞭草多糖的均一性及特征分析Example 3 Homogeneity and characteristic analysis of Verbena polysaccharide
实验方法:采用高效液相色谱法鉴定马鞭草多糖VOP的均一性和分子量。具体方法是:使用超纯水为流动相,sugar ks-804色谱柱,柱温使50℃,流速为1mL/min,使用示差折光检测器检测。根据葡聚糖标准品的出峰时间,制作分子量标准曲线,计算VOP的重均分子质量。取0.5mg/mL的VOP水溶液进行紫外-可见光全波长扫描(190-800nm)。使用红外光谱(FTIR)法分析样品的主要官能团,确认化合物类型。Experimental method: The homogeneity and molecular weight of Verbena polysaccharide VOP were identified by high performance liquid chromatography. The specific method is: using ultrapure water as the mobile phase, sugar ks-804 chromatographic column, the column temperature is 50 ° C, the flow rate is 1 mL/min, and the differential refraction detector is used for detection. According to the peak time of the dextran standard, a molecular weight standard curve was prepared, and the weight-average molecular mass of VOP was calculated. Take 0.5 mg/mL VOP aqueous solution for UV-Vis full-wavelength scanning (190-800 nm). The main functional groups of the samples were analyzed by infrared spectroscopy (FTIR) to confirm the compound type.
为分析VOP的单糖组成,取20-30mg VOP用1mol/L硫酸在100℃水解8h,碳酸钡中和样品,离心取上清液进行冷冻干燥,得到干燥的水解产物。将彻底干燥的VOP水解产物进行三甲基硅醚化衍生,衍生物进行气相色谱分析,使用hp-5毛细管色谱柱,程序升温160℃→180℃(20℃/min)→220℃(8℃/min,保持2min)→250℃(2min)。To analyze the monosaccharide composition of VOP, 20-30 mg of VOP was hydrolyzed with 1 mol/L sulfuric acid at 100 °C for 8 h, the sample was neutralized with barium carbonate, and the supernatant was centrifuged and lyophilized to obtain a dry hydrolyzate. The thoroughly dried VOP hydrolyzate was derivatized with trimethylsilyl ether, and the derivative was analyzed by gas chromatography using a hp-5 capillary column with a programmed temperature of 160 °C → 180 °C (20 °C/min) → 220 °C (8 °C /min, keep for 2min)→250℃(2min).
结果:马鞭草多糖VOP的高效液相色谱结果如图7所示,结果显示VOP在6.349min仅有1个单一峰出现,峰型尖锐且对称,说明VOP均一性好。VOP水溶液经190-800nm 全波长扫描(图8),结果显示不含有杂质,纯度高。根据分子质量标准曲线(y=-4x+6.31, R2=0.99)和VOP的出峰时间,计算得出VOP的重均分子量为290kDa。VOP的红外光谱显示其在3400cm-1、2900cm-1、1100cm-1和1650cm-1均出现糖类物质的特征吸收峰。VOP 水解产物经衍生化,衍生产物的气相色谱结果如图13所示,参照标准单糖衍生物的气相色谱结果,得出VOP由半乳糖,葡萄糖,甘露糖,鼠李糖和阿拉伯糖组成,其摩尔比为 2.8:1.5:1:1:1.4。Results: The high performance liquid chromatographic results of Verbena polysaccharide VOP are shown in Figure 7. The results show that VOP only has a single peak at 6.349min, and the peak shape is sharp and symmetrical, indicating that the VOP has good uniformity. The VOP aqueous solution was scanned at the full wavelength of 190-800 nm (Fig. 8), and the results showed that it did not contain impurities and had high purity. According to the molecular mass standard curve (y=-4x+6.31, R 2 =0.99) and the peak time of VOP, the weight-average molecular weight of VOP was calculated to be 290 kDa. The infrared spectrum of VOP showed that characteristic absorption peaks of sugars appeared at 3400cm -1 , 2900cm -1 , 1100cm -1 and 1650cm -1 . The VOP hydrolyzate was derivatized, and the gas chromatography results of the derivatized products are shown in Figure 13. Referring to the gas chromatography results of standard monosaccharide derivatives, it was concluded that VOP was composed of galactose, glucose, mannose, rhamnose and arabinose, Its molar ratio is 2.8:1.5:1:1:1.4.
实施例4马鞭草多糖VOP的抗炎症作用研究Example 4 Study on the anti-inflammatory effect of Verbena polysaccharide VOP
实验方法:experimental method:
1.RAW264.7细胞的培养:使用DMEM完全培养基(含有10%血清和1%双抗),37℃,5%二氧化碳培养箱,48h传代一次。1. Cultivation of RAW264.7 cells: use DMEM complete medium (containing 10% serum and 1% double antibody), 37°C, 5% carbon dioxide incubator, passage once 48h.
2.细胞毒检验:使用MTT法检测马鞭草多糖VOP对RAW264.7的细胞毒性,实验共设置五个质量浓度(600,300,150,75和25μg/mL)。2. Cytotoxicity test: MTT method was used to detect the cytotoxicity of Verbena polysaccharide VOP to RAW264.7. Five mass concentrations (600, 300, 150, 75 and 25 μg/mL) were set in the experiment.
3.抗炎症实验:使用1μg/mL脂多糖(LPS)诱导RAW264.7细胞表达各种炎症因子,建立炎症模型。实验设置空白组,阴性对照组和阳性对照组(地塞米松组,DXMS),样品组(VOP75)。首先提取各组细胞内总RNA,反转录后得到相应的cDNA,实时荧光定量PCR测定CT值,2-ΔΔCT法计算mRNA相对表达量(以持家基因GAPDH为内参基因),上述具体实验步骤均按照试剂盒说明书进行。3. Anti-inflammatory experiment: 1μg/mL lipopolysaccharide (LPS) was used to induce RAW264.7 cells to express various inflammatory factors to establish an inflammation model. The experiment set blank group, negative control group, positive control group (dexamethasone group, DXMS), sample group (VOP75). First, the total RNA in each group was extracted, and the corresponding cDNA was obtained after reverse transcription. The CT value was determined by real-time fluorescence quantitative PCR, and the relative mRNA expression was calculated by the 2 -ΔΔCT method (with the housekeeping gene GAPDH as the internal reference gene). The above specific experimental steps were all Follow the kit instructions.
实验结果:细胞毒实验结果如图14所示,添加75μg/mL的马鞭草多糖VOP对RAW264.7 细胞生长抑制率在20%以下,说明基本没有细胞毒性。抗炎症实验结果如图15所示,相较于空白组,TNF-α、IL-1β、IL-6和COX-2四种炎症因子的阴性对照组(LPS)mRNA相对表达量均显著增加(P<0.05),说明已经成功建立了四种炎症模型。在RAW264.7细胞中添加1μg/mL脂多糖,同时添加75μg/mL质量浓度的马鞭草多糖,与阴性对照组相比,马鞭草多糖能显著降低TNF-α、IL-1β、IL-6和COX-2四种炎症因子的mRNA相对表达量(P<0.05),说明马鞭草多糖VOP有较好抗炎效果。Experimental results: The results of the cytotoxicity experiment are shown in Figure 14. The growth inhibition rate of RAW264.7 cells by adding 75 μg/mL of Verbena polysaccharide VOP is below 20%, indicating that there is basically no cytotoxicity. The results of the anti-inflammatory experiment are shown in Figure 15. Compared with the blank group, the relative expressions of TNF-α, IL-1β, IL-6 and COX-2 in the negative control group (LPS) mRNA were significantly increased ( P<0.05), indicating that four inflammatory models have been successfully established. When adding 1 μg/mL lipopolysaccharide and 75 μg/mL mass concentration of verbena polysaccharide to RAW264.7 cells, compared with the negative control group, verbena polysaccharide can significantly reduce TNF-α, IL-1β, IL-6 and The relative mRNA expression levels of the four inflammatory factors of COX-2 (P<0.05) indicated that the verbena polysaccharide VOP had a better anti-inflammatory effect.
如图16所示,相较于阴性对照组和阳性对照组,添加75μg/mL马鞭草多糖VOP能够显著降低脂多糖诱导的RAW264.7细胞中iNOS基因的mRNA相对表达量(P<0.05),且效果与阳性对照组无显著差异(P>0.05)。iNOS基因的过量表达,可以刺激机体产生过量的一氧化氮,从而损伤神经元,造成细胞损伤。As shown in Figure 16, compared with the negative control group and the positive control group, the addition of 75 μg/mL verbena polysaccharide VOP can significantly reduce the relative mRNA expression of iNOS gene in LPS-induced RAW264.7 cells (P<0.05). And the effect was not significantly different from the positive control group (P>0.05). The overexpression of iNOS gene can stimulate the body to produce excessive nitric oxide, thereby damaging neurons and causing cell damage.
实施例5马鞭草多糖VOP的抗氧化作用研究Example 5 Study on the Antioxidative Effect of Verbena Polysaccharide VOP
抗氧化实验研究:将样品配制成浓度为30mg/mL~0.0075mg/mL的水溶液。Antioxidant experimental research: The sample was prepared into an aqueous solution with a concentration of 30 mg/mL to 0.0075 mg/mL.
1.超氧阴离子清除能力的测定:参照Robak的方法,取0.1mL样品液加入1mL含557uM NADH的16mM Tris–HCl(pH8.0),1mL含45uM PMS的16mM Tris–HCl(pH 8.0),以及1mL含108uM NBT的16mM Tris–HCl(pH 8.0),25℃温浴5min,取出在560nm下测吸光值,按照清除率=(1-样品管/对照管)×100%计算抑制率。1. Determination of superoxide anion scavenging ability: according to Robak's method, take 0.1 mL of sample solution and add 1 mL of 16 mM Tris-HCl (pH 8.0) containing 557 uM NADH, 1 mL of 16 mM Tris-HCl (pH 8.0) containing 45 uM PMS, And 1mL of 16mM Tris-HCl (pH 8.0) containing 108uM NBT, incubate at 25℃ for 5min, take out and measure the absorbance at 560nm, and calculate the inhibition rate according to the clearance rate=(1-sample tube/control tube)×100%.
2.羟自由基清除作用的测定:参照Ghiselli等的方法并改进,取0.1mL样品液分别加入 0.6mL反应缓冲液(含2.67mM脱氧核糖和0.13mM EDTA),0.4mM硫酸亚铁0.2mL,2.0mM抗坏血酸0.05mL,以及20mM的H2O2 0.05mL,37℃下温浴15min,取出后加入1%硫代巴比妥酸1mL和2%三氯乙酸1mL,沸水浴15min,立即放在冰上冷却,532nm测吸光值,按照清除率=(1-样品管/对照管)×100%计算抑制率。2. Determination of hydroxyl radical scavenging: refer to the method of Ghiselli et al. and improve it, take 0.1 mL of sample solution and add 0.6 mL of reaction buffer (containing 2.67 mM deoxyribose and 0.13 mM EDTA), 0.4 mM ferrous sulfate 0.2 mL, 0.05 mL of 2.0 mM ascorbic acid and 0.05 mL of 20 mM H 2 O 2 , incubate at 37°C for 15 min, take out, add 1 mL of 1% thiobarbituric acid and 1 mL of 2% trichloroacetic acid, bath in boiling water for 15 min, and place on ice immediately After cooling, the absorbance was measured at 532 nm, and the inhibition rate was calculated according to the clearance rate=(1-sample tube/control tube)×100%.
3.ABTS自由基的测定,取100ul样品液,加入100ul ABTS工作液,室温暗处反应10min,734nm下测OD,按照清除率=(1-样品管/对照管)×100%计算抑制率。3. Determination of ABTS free radicals, take 100ul sample solution, add 100ul ABTS working solution, react in the dark at room temperature for 10min, measure OD at 734nm, and calculate the inhibition rate according to scavenging rate=(1-sample tube/control tube)×100%.
马鞭草多糖VOP的抗氧化结果如图17所示,以维生素c(Vc)作为阳性对照,VOP和Vc对超氧自由基、羟自由基和ABTS自由基的清除作用随浓度的增加而增加,均呈现量效关系。马鞭草多糖VOP对超氧自由基和ABTS自由基清除作用显著,经计算EC50分别是 287μg/mL和390μg/mL,清除作用与维生素C相当。The antioxidant results of verbena polysaccharide VOP are shown in Figure 17. Taking vitamin c (Vc) as a positive control, the scavenging effects of VOP and Vc on superoxide radicals, hydroxyl radicals and ABTS radicals increased with the increase of the concentration. Both showed a dose-response relationship. Verbena polysaccharide VOP has a significant scavenging effect on superoxide free radicals and ABTS free radicals. The calculated EC 50 is 287μg/mL and 390μg/mL, respectively, and the scavenging effect is comparable to that of vitamin C.
综上所述,添加75μg/mL马鞭草多糖VOP能够显著降低脂多糖诱导的RAW264.7细胞中炎症相关因子TNF-α、IL-1β、IL-6、COX-2和iNOS的mRNA相对表达量(P<0.05),抗炎效果显著,且无细胞毒。马鞭草多糖VOP对超氧自由基和ABTS自由基的清除效果相当于Vc,抗氧化作用显著。In conclusion, the addition of 75 μg/mL verbena polysaccharide VOP can significantly reduce the relative mRNA expression of inflammatory-related factors TNF-α, IL-1β, IL-6, COX-2 and iNOS in LPS-induced RAW264.7 cells. (P<0.05), the anti-inflammatory effect was significant, and there was no cytotoxicity. The scavenging effect of verbena polysaccharide VOP on superoxide free radicals and ABTS free radicals is equivalent to Vc, and the antioxidant effect is significant.
炎症因子过多的表达会引起多种疾病,如中枢神经系统疾病、动脉粥样硬化、慢性阻塞性肺疾患、类风湿性关节炎等,所以天然无毒抗炎制剂的开发被医药企业列为主要的研发方向之一。Excessive expression of inflammatory factors can cause a variety of diseases, such as central nervous system diseases, atherosclerosis, chronic obstructive pulmonary disease, rheumatoid arthritis, etc. Therefore, the development of natural non-toxic anti-inflammatory preparations is listed as a pharmaceutical company. One of the main research and development directions.
人体因与外界接触,包括呼吸,放射线,空气污染等因素,体内会不断产生自由基。科学研究表明,过量产生的自由基与衰老、心血管疾病、关节炎、癌症等密切关联,抗炎和抗氧化相辅相成,因为自由基也是导致肌肤产生炎症的“元凶”之一,所以市面上很多化妆品都含有抗炎和抗氧化成分,寻找天然无毒的抗炎和抗氧产品也是市场上最重要的功能性诉求之一。The human body will continuously generate free radicals due to contact with the outside world, including breathing, radiation, air pollution and other factors. Scientific research shows that excessive free radicals are closely related to aging, cardiovascular disease, arthritis, cancer, etc. Anti-inflammatory and antioxidant complement each other, because free radicals are also one of the "culprits" that cause skin inflammation, so there are many on the market. Cosmetics all contain anti-inflammatory and antioxidant ingredients, and finding natural and non-toxic anti-inflammatory and antioxidant products is also one of the most important functional demands on the market.
以上所述,仅为本发明的较佳实施例而已,故不能依此限定本发明实施的范围,即依本发明专利范围及说明书内容所作的等效变化与修饰,皆应仍属本发明涵盖的范围内。The above are only the preferred embodiments of the present invention, so the scope of implementation of the present invention cannot be limited accordingly, that is, equivalent changes and modifications made according to the patent scope of the present invention and the contents of the description should still be covered by the present invention. In the range.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110974761.7A CN113603802B (en) | 2021-08-24 | 2021-08-24 | Preparation method and application of verbena polysaccharide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110974761.7A CN113603802B (en) | 2021-08-24 | 2021-08-24 | Preparation method and application of verbena polysaccharide |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113603802A CN113603802A (en) | 2021-11-05 |
CN113603802B true CN113603802B (en) | 2022-10-14 |
Family
ID=78309240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110974761.7A Active CN113603802B (en) | 2021-08-24 | 2021-08-24 | Preparation method and application of verbena polysaccharide |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113603802B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113956369B (en) * | 2021-10-21 | 2022-09-27 | 河南省医药科学研究院 | Preparation method and application of Caryopteris clandonensis polysaccharide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109265576A (en) * | 2018-09-27 | 2019-01-25 | 广东药科大学 | A kind of macromolecule astragalus polyose and the preparation method and application thereof with anti-inflammatory activity |
CN113278090A (en) * | 2021-06-28 | 2021-08-20 | 华侨大学 | Albizzia julibrissin polysaccharide, preparation method and application |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1251615B (en) * | 1991-10-04 | 1995-05-17 | Golgi Sa | ANTIELASTASIC ACTIVITY MEDICATION. |
DE10310267A1 (en) * | 2003-03-10 | 2004-09-23 | Anoxymer Gmbh | Intramolecular transesterification of material, especially plant extract, containing cyclic polyhydroxy compounds, e.g. to prepare bioactive natural products, carried out at elevated temperature and pressure |
KR101289432B1 (en) * | 2012-08-30 | 2013-07-24 | (주)모아캠 | Extract containing polyssacharide derived from lippia citriodora and cosmetic composition containing the same |
CN104945531B (en) * | 2015-07-16 | 2017-01-18 | 安徽工程大学 | Gentian acidity uniform polysaccharide and purification method and application thereof |
CN110551233B (en) * | 2019-09-29 | 2021-06-25 | 中国药科大学 | A kind of Guangdong Zizhu polysaccharide and its extraction method and use |
CN112794931A (en) * | 2021-01-28 | 2021-05-14 | 四川大学 | A kind of tofu Chaiye RG-I pectin with antioxidant and anti-inflammatory activity and preparation method and application thereof |
-
2021
- 2021-08-24 CN CN202110974761.7A patent/CN113603802B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109265576A (en) * | 2018-09-27 | 2019-01-25 | 广东药科大学 | A kind of macromolecule astragalus polyose and the preparation method and application thereof with anti-inflammatory activity |
CN113278090A (en) * | 2021-06-28 | 2021-08-20 | 华侨大学 | Albizzia julibrissin polysaccharide, preparation method and application |
Non-Patent Citations (1)
Title |
---|
中药马鞭草抗炎作用研究进展;董玲等;《科技经济导刊》;20200115(第02期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN113603802A (en) | 2021-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Extraction optimization, physicochemical properties and antioxidant and hypoglycemic activities of polysaccharides from roxburgh rose (Rosa roxburghii Tratt.) leaves | |
CN104987433B (en) | Preparation method of RG-I type lycium barbarum pectin with anti-aging activity | |
CN109651532B (en) | Dendrobium officinale glucomannan | |
CN106317246A (en) | Anti-oxidation polysaccharide in boletus subsplendidus as well as preparation method and application thereof | |
CN111019008A (en) | Anti-inflammatory activity phellinus igniarius polysaccharide SHP and preparation method thereof | |
CN113603802B (en) | Preparation method and application of verbena polysaccharide | |
CN111196864B (en) | Dendrobium nobile polysaccharide with moisturizing effect and preparation method and application thereof | |
CN106674368A (en) | Preparation method of phellinus igniarius sporocarp cell wall active crude polysaccharide | |
CN107012184B (en) | Angelica dahurica polysaccharide extracted by enzyme method, preparation method and application thereof | |
CN114874348B (en) | Vaccinium bracteatum thunb leaf polysaccharide VBLP-3b and preparation method and application thereof | |
CN112062866A (en) | Hericium erinaceus selenium-rich polysaccharide and preparation method and application thereof | |
CN113603801B (en) | An extraction method for obtaining two kinds of summer-free polysaccharides, two kinds of summer-free polysaccharides and applications thereof | |
CN104997034B (en) | Anti-oxidant sea-buckthorn HG type pectin dietary fibers and its isolation and purification method and application | |
CN110655593B (en) | Menthol polysaccharide composition and its preparation method and application | |
CN113527529B (en) | Aleuritopteris argentea fee polysaccharide and preparation method and application thereof | |
CN109234335B (en) | A kind of preparation method of polysaccharide rich in galactofuranos in bamboo yellow | |
CN115073620B (en) | Two homogeneous blackberry lily polysaccharides with anticomplementary activity and preparation method and application thereof | |
CN111647095B (en) | Polysaccharide of fraxinus chinensis, preparation method and application thereof | |
CN112107590A (en) | Application of swim bladder-derived heparin mucopolysaccharide in preparation of angiogenesis inhibitor | |
CN107090050B (en) | Screwtree root polysaccharide and preparation method thereof and preparing the purposes in anticomplement medicament | |
CN112674254B (en) | A kind of corn bract leaf polysaccharide hypoglycemic effervescent tablet and preparation method thereof | |
CN116731217B (en) | Ampelopsis grossedentata acidic polysaccharide AGP-2a, preparation method thereof and application thereof in preparing anti-inflammatory cosmetics | |
CN116655820B (en) | Ampelopsis grossedentata acidic polysaccharide AGP-3a, extraction and separation method thereof and application thereof in preparation of anti-inflammatory cosmetics | |
CN118221838A (en) | Preparation and new application of new genkwa polysaccharide | |
CN118496393A (en) | Preparation method and application of blackberry lily degradation polysaccharide with high anticomplement activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |